Results 61 to 70 of about 6,725 (159)

Drug Repurposing for the Discovery of Potential Inhibitors Targeting DJ-1 (PARK7) Against Parkinson’s Disease

Crystals
Parkinson’s disease (PD) is a neurodegenerative disease characterized by increased movement dysfunction and cognitive loss. DJ-1 (PARK7) is an antioxidant that protects cells from oxidative stress, a major contributor to cellular damage and ...
Taibah Aldakhil, Ali Altharawi
doaj   +1 more source

GX15-070 enhances niraparib efficacy in ovarian cancer by promoting a shift in Mcl1-mediated DNA repair pathway from HR to NHEJ

Journal of Translational Medicine
Background PARP inhibitor (PARPi) maintenance therapy significantly extends progression-free survival of patients with homologous recombination repair deficiency (HRD) or BRCA mutations in ovarian cancer.
Jia-Jia Sheng, Yan He, Po-Wu Liu, Sheng-An Zheng, Nayiyuan Wu, Hong-Ying Sui, Quan Cheng, He Li   +7 more
doaj   +1 more source

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer

Journal of Comparative Effectiveness Research
Aim: To understand the impact of the niraparib individualized starting dose (ISD), compared with fixed starting dose (FSD), on the cost of hematologic adverse event (AE) management from a US payer perspective.
Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O’Malley, Domenica Lorusso, Ashley F Haggerty, Michel Fabbro, John K Chan, Florian Heitz, Lyndsay J Willmott, Ilan Bruchim, Ying Zhuo, Purificacion Estevez-Garcia, Bradley J Monk, Hannelore Denys, Anja Knudsen, Anna V Tinker, Luis Manso Sanchez, Diane Provencher, Maria Pilar Barretina-Ginesta, John Hartman, Donna V Booth, Antonio Gonzalez-Martin   +23 more
doaj   +1 more source

Nephrotoxicity Associated With Niraparib [PDF]

American Journal of Kidney Diseases, 2020
Hélène, Lazareth, Nicolas, Delanoy, Raphaël, Cohen, Emilie, Boissier, Hamza, Ayari, Pierre, Combe, Céline, Crespel, Elise, Mercadier-Riaz, Alexandre, Karras, Marie, Courbebaisse, Eric, Thervet, Nicolas, Pallet   +11 more
openaire   +2 more sources

Hyperthermia-induced BRCA2 reduction potentiates PARPi sensitivity in BRCA2-proficient ovarian carcinoma

Discover Oncology
Background BRCA2-proficient ovarian cancer (OVCA) exhibits resistance to poly (ADP-ribose) polymerase-1 (PARP) inhibitors (PARPi). This study aims to exploit hyperthermia (HT)-induced BRCA2 reduction as a strategy to enhance OVCA sensitivity to PARPi ...
Bingjie Mei, Junyang Li, Xiaoyu Hou, Jie Zhang, Dengfeng Wang, Jianming Huang, Guonan Zhang   +6 more
doaj   +1 more source

Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report

Frontiers in Pharmacology
BackgroundNiraparib, a poly ADP-ribose polymerase inhibitors (PARPi), has been widely applied in the intervention of epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Xiaolong Yue, Chenkang Yang, Dandan Cao, Yue Li   +3 more
doaj   +1 more source

Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer

Scientific Reports
Poly (ADP-ribose) polymerase inhibitors have been increasingly used in ovarian cancer treatment. However, the real-world safety data of these drugs in Japanese patients are limited.
Ryosuke Uekusa, Akira Yokoi, Eri Watanabe, Kosuke Yoshida, Masato Yoshihara, Satoshi Tamauchi, Yusuke Shimizu, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kaoru Niimi, Shiro Suzuki, Hiroaki Kajiyama   +11 more
doaj   +1 more source

Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant BRCA1-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge

Cells
Poly (ADP-ribose) polymerase inhibitors (PARPis) show cytotoxicity in homologous recombination deficiency (HRD) seen in BRCA-mutant ovarian cancer (OvCa). Despite initial responses, resistance often develops.
Chi-Ting Shih, Tzu-Ting Huang, Jayakumar R. Nair, Kristen R. Ibanez, Jung-Min Lee   +4 more
doaj   +1 more source

Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study

Oncology and Therapy
Introduction Niraparib first-line maintenance (1LM) therapy has demonstrated clinical benefit for patients with ovarian cancer (OC) in clinical trial and real-world settings, but data on factors associated with real-world patient outcomes remain limited.
Dana M. Chase, Soham Shukla, Julia Moore, Tirza Areli Calderón Boyle, Jonathan Lim, Jessica Perhanidis, Jean A. Hurteau, Jeanne M. Schilder   +7 more
doaj   +1 more source

Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study

Oncology and Therapy
Introduction Clinical trials have demonstrated prolonged survival associated with niraparib first-line maintenance (1LM) therapy, compared with placebo, for patients with ovarian cancer (OC).
Bobbie Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M. Schilder, Jean A. Hurteau, Amanda Golembesky   +8 more
doaj   +1 more source